Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

NCT04606446 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04606446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04606446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
November 16, 2020
Completion date
August 10, 2029
Enrollment
320 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic castration-resistant prostate cancer, locally advanced or metastatic er+ her2- breast cancer, locally advanced or metastatic non-small cell lung cancer